BRPI0811476A2 - Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível - Google Patents

Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível

Info

Publication number
BRPI0811476A2
BRPI0811476A2 BRPI0811476-5A2A BRPI0811476A BRPI0811476A2 BR PI0811476 A2 BRPI0811476 A2 BR PI0811476A2 BR PI0811476 A BRPI0811476 A BR PI0811476A BR PI0811476 A2 BRPI0811476 A2 BR PI0811476A2
Authority
BR
Brazil
Prior art keywords
reversible
intravenous
inhibitor
direct
oral dosage
Prior art date
Application number
BRPI0811476-5A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert M Scarborough
Daniel D Gretler
Pamela B Conley
Patrick Andre
Athiwat Hutchaleelaha
David R Philips
Anjali Pandey
Huang Wolin
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of BRPI0811476A2 publication Critical patent/BRPI0811476A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0811476-5A2A 2007-05-02 2008-05-02 Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível BRPI0811476A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91564907P 2007-05-02 2007-05-02
US94792107P 2007-07-03 2007-07-03
PCT/US2008/062518 WO2008137753A2 (en) 2007-05-02 2008-05-02 Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor

Publications (1)

Publication Number Publication Date
BRPI0811476A2 true BRPI0811476A2 (pt) 2014-11-04

Family

ID=39587015

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811476-5A2A BRPI0811476A2 (pt) 2007-05-02 2008-05-02 Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível

Country Status (17)

Country Link
US (2) US20090048216A1 (enExample)
EP (1) EP2079464A2 (enExample)
JP (1) JP2010526101A (enExample)
KR (1) KR20100029746A (enExample)
CN (1) CN101795682A (enExample)
AU (1) AU2008247483A1 (enExample)
BR (1) BRPI0811476A2 (enExample)
CA (1) CA2686203A1 (enExample)
CO (1) CO6241104A2 (enExample)
EA (1) EA200901473A1 (enExample)
EC (1) ECSP099778A (enExample)
GT (1) GT200900284A (enExample)
IL (1) IL201834A0 (enExample)
MA (1) MA31663B1 (enExample)
MX (1) MX2009011843A (enExample)
TN (1) TN2009000451A1 (enExample)
WO (1) WO2008137753A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8058284B2 (en) * 2005-11-03 2011-11-15 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto
AU2008223831B2 (en) * 2007-03-06 2012-07-05 Novartis Ag Bicyclic organic compounds suitable for the treatment of inflammatory or allergic conditions
EA200901474A1 (ru) * 2007-05-02 2010-04-30 Портола Фармасьютиклз, Инк. Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе
US20090156620A1 (en) * 2007-05-02 2009-06-18 Portola Pharmaceuticals, Inc. [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
JP5851246B2 (ja) * 2008-12-30 2016-02-03 リグスホスピタルＲｉｇｓｈｏｓｐｉｔａｌｅｔ 臓器不全の発生リスクが上昇した重篤患者を識別する方法およびその治療のための化合物
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
ES2548845T3 (es) * 2009-12-23 2015-10-21 Ratiopharm Gmbh Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico
WO2011088152A1 (en) 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
WO2011137459A1 (en) * 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2012072743A1 (en) * 2010-12-01 2012-06-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and kits for determining platelet susceptibility to activation in a patient
CN103339126B (zh) * 2010-12-03 2016-06-29 博尔托拉制药公司 式(i)化合物的固态形式及其药物组合物、剂型和使用方法
US11179390B2 (en) 2017-03-15 2021-11-23 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a P2Y12 receptor antagonist
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY
CN107462648B (zh) * 2017-08-21 2019-09-27 盐城锦明药业有限公司 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
US8058284B2 (en) 2005-11-03 2011-11-15 Portola Pharmaceuticals, Inc. [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Also Published As

Publication number Publication date
MX2009011843A (es) 2010-04-22
KR20100029746A (ko) 2010-03-17
WO2008137753A3 (en) 2009-02-12
IL201834A0 (en) 2010-06-16
GT200900284A (es) 2012-01-31
JP2010526101A (ja) 2010-07-29
MA31663B1 (fr) 2010-09-01
TN2009000451A1 (en) 2011-03-31
CA2686203A1 (en) 2008-11-13
EP2079464A2 (en) 2009-07-22
EA200901473A1 (ru) 2010-06-30
US20120009172A1 (en) 2012-01-12
CO6241104A2 (es) 2011-01-20
US20090048216A1 (en) 2009-02-19
WO2008137753A2 (en) 2008-11-13
ECSP099778A (es) 2010-01-29
AU2008247483A1 (en) 2008-11-13
CN101795682A (zh) 2010-08-04

Similar Documents

Publication Publication Date Title
IL201834A0 (en) Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
DK2277509T3 (da) DPP IV inhibitorformuleringer
EP2047820A4 (en) ORTHODONTIC FASTENING BRIDGE
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
BRPI0918360A2 (pt) composto, composição farmacêutica e usos de um composto
EP2133096A4 (en) IN THE MOUTHING TABLET
EP2132133A4 (en) RELEASE OF PARTICULATE ACTIVE SUBSTANCES
DK2399580T3 (da) Farmaceutiske doseringsformer
EP2147437A4 (en) SEEDING REPLICATION
BRPI0720100A2 (pt) Implemento para cuidado oral
PT2397142T (pt) Utilizações de inibidores da dpp iv
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0808016A2 (pt) Dispositivos ortodônticos
GB0703438D0 (en) Preventing spread of infection
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
ATE493119T1 (de) Pharmazeutische zusammensetzung
HRP20192282T8 (hr) Inhibitori tfpi i postupci upotrebe
DK2018158T3 (da) Ny racecadotril administrationsform
EP2185112A4 (en) Stabilized therapeutic compositions and formulations
DE602007010119D1 (de) Mundpflegezusammensetzung mit silikonverbund
IL192319A (en) Assessment of medical conditions
IL202765A0 (en) Pharmaceutical combination of nsaid and prostaglandin compound
PT2271348T (pt) Formulação de comprimido oral de composto de tetraciclina
DE602008005137D1 (de) Chinolonverbindung und pharmazeutische zusammensetzung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]